If there is one topic that stops women in their tracks the moment it comes up, it's this one.

Hormone Replacement Therapy.

I see it every day in my practice.

Women don't arrive with a neutral question. They arrive with a story already written — one they've been carrying for years, sometimes decades.

"I've heard it's dangerous."

"I've heard it causes cancer."

"I'd rather just go through it naturally."

And at the same time, their body is telling a very different story.

They wake up at 3am, heart racing, sheets damp. Their energy has shifted in a way that has nothing to do with how they eat or move. Their joints feel stiffer than they used to. Their memory skips in ways that unsettle them. Their mood feels… unfamiliar. Like they're watching themselves from a slight distance.

So the question becomes simple — and heavy:

Should I take hormones… or not?

What menopause actually is

For years, your body has been running a finely tuned conversation.

Your brain — specifically the hypothalamus — sends hormonal signals. Your ovaries receive them, respond, and produce estrogen and progesterone in a rhythm that shapes your entire cycle. It's a back-and-forth that happens month after month, decade after decade.

Then, gradually, the conversation changes.

The brain keeps sending signals — sometimes even more urgently than before. But the ovaries don't respond in the same way they used to. The messages become less precise. Cycles shift. Ovulation becomes irregular. Hormone levels start to fluctuate more dramatically than at any point since puberty.

This is perimenopause.

And when ovulation stops and hormone production drops significantly, we reach menopause.

Not a sudden switch. Not a collapse. A shift in communication — one that, for a while, can feel like chaos.

Why symptoms can feel so intense

What many women experience during this transition isn't simply "low hormones."

It's instability.

One week estrogen climbs. The next, it drops. Progesterone becomes unreliable because ovulation is no longer consistent. And this hormonal turbulence shows up everywhere — in sleep, in mood, in energy, in the sharpness (or fogginess) of thought.

Your body is not breaking down.

It's recalibrating. And recalibration, while it's happening, can feel like everything is off at once.

Where the fear around HRT comes from

To understand why so many women hesitate, we need to go back to 2002.

That's when results from the Women's Health Initiative were published — one of the largest studies ever conducted on postmenopausal women. The finding that reached the headlines was simple:

Hormone therapy increases the risk of breast cancer.

And that sentence spread fast.

Within months, HRT prescriptions dropped by 60–70% worldwide. Millions of women stopped treatment almost overnight. It was one of the most rapid shifts in medical practice in modern history.

But nuance was lost.

What the study actually showed

The research looked at women taking a combination of estrogen and a synthetic progestin. The highlighted numbers were striking — a 26% increase in relative risk of breast cancer, a 29% increase in coronary heart disease.

On paper, alarming.

But context changes everything.

In absolute terms, the numbers looked like this: approximately 38 cases of breast cancer per 10,000 women per year on HRT, compared to 30 cases per 10,000 women per year without it. That's 8 additional cases per 10,000 women per year.

Still relevant. But very different from how the public heard it.

Relative risk sounds dramatic. Absolute risk gives perspective — and perspective was barely offered.

The word "cancer" travels fast, and the nuance rarely catches up.

What was overlooked

When researchers went back to examine the data more carefully, several things stood out.

The average age of women in the study was 63. Many had started hormone therapy 10 to 15 years after menopause had already begun — which, from a physiological standpoint, is a very different situation from starting treatment when symptoms first appear.

Many participants also had underlying cardiovascular risk factors that weren't fully accounted for.

And the formulation used — oral conjugated equine estrogens combined with a synthetic progestin — is quite different from what is commonly prescribed today. Modern HRT is increasingly moving toward bioidentical estradiol and progesterone: molecules that are structurally identical to the ones your body produces naturally, and that are metabolised in a way that more closely reflects normal physiology.

In other words, the study was not looking at the typical woman in her late 40s or early 50s sitting across from me asking: "What can help me feel like myself again?"

What we understand today

Over the past two decades — including large re-analyses through 2024 — a clearer picture has emerged.

Timing matters enormously.

When hormone therapy is started closer to menopause, in healthy women, the risk profile looks very different. We see no significant increase in cardiovascular risk in many cases. We even see a potential reduction in coronary heart disease when therapy begins early. And we see clear, consistent improvement in quality of life.

The breast cancer conversation has also become more nuanced.

The increased risk appears to be mainly linked to combined estrogen and synthetic progestin therapy. Estrogen-only therapy, in women without a uterus, does not show the same pattern — and in some analyses, has even suggested a slight reduction in risk.

How hormones are delivered also matters. Transdermal estrogen — absorbed through the skin rather than processed through the liver — carries a different risk profile than oral therapy. The clotting and cardiovascular risks that featured so prominently in the original headlines appear to be largely specific to oral routes. This distinction wasn't part of the 2002 conversation. It is now.

The data is not simple. But it is far less frightening than the headline suggested.

The concept of timing — why it changes everything

This is where everything shifts.

Hormones work by binding to receptors in your tissues. Think of them as keys, and the receptors as locks. When you introduce hormones while the system is still responsive and active, the body knows what to do with them.

Wait too long, and the response changes. The receptors become less sensitive. The tissue has adapted — or started to adapt — to the absence.

Same hormones. Very different outcome.

This is why starting HRT within the first ten years of menopause, or before age 60, is where the evidence consistently points to the most benefit and the most favourable risk profile. Not because the window closes completely — but because the body is most receptive early.

What HRT actually does

Hormone therapy doesn't restart your ovaries or bring back ovulation.

What it does is provide the hormones that your body is no longer producing in sufficient amounts — and in doing so, it steadies the system. It reduces the peaks and crashes. It supports the transition rather than letting your body navigate it alone in chaos.

Beyond the relief of symptoms, estrogen plays a meaningful role in bone density, cardiovascular health, and brain function. As levels decline, risks in all three areas gradually increase. Hormone therapy, used appropriately and at the right time, can support these systems as part of a broader approach to long-term health.

It's not a magic solution. Nothing is.

But it is a real one — and for many women, a genuinely important one.

Is it for everyone?

No. And I say that honestly, not to hedge.

There are women for whom HRT is not appropriate — those with certain hormone-sensitive cancers, unexplained vaginal bleeding, or a history of blood clots, among others. The decision always depends on your individual history, your current health, and the timing relative to your menopause.

There is no universal prescription. There is only the right decision for your body, your situation, and your life.

Why doesn't my doctor always bring it up?

Because medicine is not as unified on this topic as we might hope.

Some gynaecologists are very comfortable prescribing HRT. Others remain cautious. Some still carry the weight of what was taught in medical school during the post-WHI years, when the message was clear and unqualified: hormones increase risk.

Once that message settles into medical culture, it takes time to shift — even as the evidence evolves.

Today, major medical societies — including the British Menopause Society and the Swiss Society of Gynaecology and Obstetrics (SGGG) are aligned on this: for healthy women under 60, or within ten years of menopause, HRT can be a safe and effective option when prescribed appropriately. The SGGG's most recent guidance, updated in January 2025, goes further — explicitly recommending bioidentical hormones as the preferred option, and confirming that treatment duration should not be arbitrarily limited.

But guidelines require interpretation. And interpretation varies between practitioners.

A question worth sitting with

Something I notice often: many women are more afraid of taking hormones than they are of years of disrupted sleep, progressive bone loss, and increasing cardiovascular risk.

Both are choices. Both carry consequences.

What matters is that the choice is informed — and yours.

If your doctor doesn't mention HRT, it doesn't mean it isn't appropriate for you. It may simply mean they're more cautious, or that they're reading the research through a different lens. Ask questions. Ask what applies specifically to your situation. And if you need another perspective, seek one — not because someone is necessarily right or wrong, but because this is an area where individual context matters deeply.

One last thing

You have spent your entire life in rhythm with your hormones. They have shaped your energy, your mood, your body, your sense of self — in ways so constant that you may not have noticed them until they started to shift.

Menopause doesn't end that relationship.

It changes it.

And once you understand what's actually happening — and what your real options are — you stop feeling lost in your body and start making decisions from a place of clarity.

That clarity is what you deserve.

Reference

Burger, H. (2003). Hormone replacement therapy in the post-Women's Health Initiative era: Report of a meeting held in Funchal, Madeira, February 24–25, 2003. Climacteric, 6(Suppl. 1), 11–36. https://pubmed.ncbi.nlm.nih.gov/12945798/

Modena, M. G., Sismondi, P., Mueck, A. O., Kuttenn, F., de Lignières, B., Verhaeghe, J., Foidart, J. M., Caufriez, A., & Genazzani, A. R. (2005). New evidence regarding hormone replacement therapies: Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas, 52(1), 1–10. https://pubmed.ncbi.nlm.nih.gov/15963666/

Manson, J. E., Crandall, C. J., Rossouw, J. E., et al. (2024). The Women's Health Initiative randomized trials and clinical practice: A review. JAMA, 331(20), 1748–1760. https://pubmed.ncbi.nlm.nih.gov/38691368/

Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. https://jamanetwork.com/journals/jama/fullarticle/195120